Aberdeen Hospital Antibiotic Susceptibility (January 1, 2017 to December 31, 2017)

Inpatients - Gram Negative Isolates: % Susceptible

Piperacillin/Tazobactam
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin

Tetracycline2
Meropenem
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
# tested **

Ertapenem
Ampicillin

SXT/TMP
E. coli 127 81 52 82 92 92 93 100 99 70 91 78 72 89 88
Klebsiella pneumoniae
39 100 R 95 95 95 97 100 100 95 39 95 87 100 100
ssp pneumoniae
Klebsiella oxytoca 85 89 R 54 100 94 89 100 100 100 92 100 97 100 100
Citrobacter freundii 37 R R R 62* 62* R 97 97 87 97 89 87 87 89
Enterobacter cloacae 147 R R R 67* 61* R 86 97 97 54 92 89 99 99
Enterobacter
37 R R R 65* 65* R 89 97 95 R 100 92 100 100
aerogenes 4
Serratia marcescens 90 R R R 99 91 - 98 100 90 R 100 21 99 93
Morganella morganii 45 R R R 91 91 98 100 100 89 R 82 24 98 79
Proteus mirabilis 174 99 87 86 99 98 100 99 100 93 R 88 R 94 94
Afermenters
Pseudomonas
49 R R R 87 R 86 R 96 82 R R R 93 100
aeruginosa
Burkholderia cepacia 3 27 R R R 33 15 R R 78 26 - 48 - R R
Stenotrophomonas sp. 36 R R R 39 - - R R 28 - 92 - 19 22
Acinetobacter
60 R R R 78 18 82 - 100 98 - 98 - 97 100
baumannii complex 3

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results
Includes inpatient and outpatient samples
* may develop resistance on treatment due to inducible AmpC B-lactamase (not Susceptibility <50% 50-89% ≥90%
recommended for treatment for Enterobacter and Citrobacter)
** approximate # tested as not all isolates tested against all antibiotics
“R” intrinsically resistant or sensitivity <10%
“-“either not tested or not active
1 for uncomplicated UTI only
2 doxycycline susceptibility can be inferred
3 includes isolates from Oct 2014-Sept 2017 (due to low number of isolates)
4 Enterobacter aerogenes now called Klebsiella aerogenes

Species in green indicate susceptibility rates from QEII HSC Data due to low number local isolates
 Inpatients - Gram Positive Isolates: % Susceptible (January 1, 2017 to December 31, 2017)

Amoxicillin/Clavulanate

Nitrofurantoin9
Erythromycin

Ciprofloxacin

Levofloxacin
Clindamycin

Vancomycin
doxycycline
Ceftriaxone
Cloxacillin8
# tested**

Ampicillin

SXT/TMP
Penicillin
Staphylococcus aureus 1 538 882 R R 88 - 77 71 83 - 99 98 986 100
MRSA 64 R R R R R 33 16 19 - 100 95 986 98
Coagulase negative
217 372 - - 37 - 58 43 46 - 99 61 926 100
Staphylococcus
Enterococcus spp10 39 - 89 89 - - R R 38 38 95 - 24 98
Enterococcus faecalis 87 992 99 -7 R R R R 83 - 98 R 28 100
Enterococcus faecium 53 R2 R -7 R R R R R - R R 21 98
Streptococcus pyogenes
4,10
38 1003 1003 1003 1003 1003 84 84 - - - R - 1003
(Group A Streptococcus)
Streptococcus pneumoniae
5,10 64 692 692 69 - 100 - 71 - 98 - - 76 1003

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results
** approximate # tested as not all isolates tested against all antibiotics
“R” intrinsically resistant or susceptibility < 10% Susceptibility <50% 50-89% ≥90%
“-“ either not tested or not active
MRSA = methicillin resistant Staphylococcus aureus
1 includes MRSA which represents approximately 12% of all S. aureus isolates
2 inferred susceptibility from other agents.
3 predicted susceptibility from literature
5 non-CSF isolates (CSF isolates may have higher resistance due to lower MIC breakpoints for penicillin and ceftriaxone)
6 doxycycline susceptibility can be inferred
7 may be susceptible but not reported (not better than ampicillin)
8 cefazolin and cephalexin susceptibilities can be inferred from cloxacillin
9 for uncomplicated UTI only
10 primarily urinary isolates (not speciated – see QEII HSC data for specific species)

Species in green indicate susceptibility rates from QEII HSC Data due to low number local isolates
 Outpatients - Gram Negative Isolates: % Susceptible (January 1, 2017 to December 31,
2017)

Piperacillin/Tazobactam
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin

Tetracycline2
Meropenem
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
# tested **

Ertapenem
Ampicillin

SXT/TMP
E. coli 1667 81 60 87 94 94 95 100 100 83 97 82 83 93 93
Klebsiella pneumoniae
267 97 R 98 98 98 98 100 100 95 53 94 90 99 98
ssp pneumoniae
Klebsiella oxytoca 159 89 R 55 99 94 94 100 100 99 77 94 95 98 99
Citrobacter freundii 39 R R R 85* 82* 85 100 100 92 97 92 67 97 97
Enterobacter cloacae
49 R R R 85* 83* 87 100 98 100 23 91 93 100 100
complex
Enterobacter
79 R R R 90* 87* 87* 98 98 96 14 96 98 100 100
aerogenes 4
Proteus mirabilis 182 100 82 63 96 96 99 100 99 97 R 66 R 92 92
Afermeters
Pseudomonas
85 R R R 94 R 88 R 90 95 R R R 95 100
aeruginosa
Burkholderia cepacia 3 33 R R R 30 R R R 61 R - R - R R
Stenotrophomonas
55 R R R 35 R - - R 13 - 91 - 13 R
sp.
Acinetobacter
46 R R R 94 24 90 - 100 98 - 100 - 100 100
baumannii complex 3

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results
* may develop resistance on treatment due to inducible AmpC B-lactamase (not recommended for treatment for Enterobacter and Citrobacter)
** approximate # tested as not all isolates tested against all antibiotics
“R” intrinsically resistant or sensitivity <10%
“-“ either not tested or not active Susceptibility <50% 50-89% ≥90%
1 for uncomplicated UTI only
2 doxycycline susceptibility can be inferred
3 includes isolates from Sept 2015 – Oct 2017
4 Enterobacter aerogenes now called Klebsiella aerogenes

Species in green indicate susceptibility rates from QEII HSC Data due to low number local isolates
 Outpatients - Gram Positive Isolates: % Susceptible (January 1, 2017 to December 31, 2017)

Amoxicillin/Clavulanate

Nitrofurantoin9
Erythromycin

Ciprofloxacin

Levofloxacin
Clindamycin

Vancomycin
doxycycline
Ceftriaxone
# tested **

Cloxacillin8
Ampicillin

SXT/TMP
Penicillin
Staphylococcus aureus 1 949 88 - - 88 - 72 63 84 - 99 97 936 100
MRSA 109 R R R R R 52 27 34 - 99 93 1006 100
Coagulase negative
170 422 - - 42 - 62 49 44 - 99 61 - 98
Staphylococcus
Enterococcus spp 234 - 98 97 - - R R 70 72 95 - 26 100
Enterococcus faecalis 240 992 99 -7 R R R R 64 - 98 R 28 100
Enterococcus faecium 63 102 10 -7 R R R R 44 - R R 16 100
Streptococcus pyogenes 4,10
38 1003 1003 1003 1003 1003 84 84 - - - R - 1003
(Group A Streptococcus)
Streptococcus pneumoniae
5,10 64 692 692 69 - 100 - 71 - 98 - - 77 1003

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results Susceptibility <50% 50-89% ≥90%
** approximate # tested as not all isolates tested against all antibiotics
“R” intrinsically resistant or susceptibility < 10%
“-“ either not tested or not active
MRSA = methicillin resistant Staphylococcus aureus
1 includes MRSA which represents approximately 11% of all S. aureus isolates
2 inferred susceptibility from other agents.
3 predicted susceptibility from literature
5 non-CSF isolates (CSF isolates may have higher resistance due to lower MIC breakpoints for penicillin and ceftriaxone)
6 doxycycline susceptibility can be inferred
7 may be susceptible but not reported (not better than ampicillin)
8 cefazolin and cephalexin susceptibilities can be inferred from cloxacillin
9 for uncomplicated UTI only

Species in green indicate susceptibility rates from QEII HSC Data due to low number local isolates
 E. coli and Klebsiella pneumoniae (urinary isolates only): % Susceptible
(January 1, 2017 to December 31, 2017)

Piperacillin/Tazobactam
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin
Meropenem

Tetracycline
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
Ertapenem
Ampicillin

SXT/TMP
# tested

Inpatient Urine
E. coli 118 79 51 82 91 91 92 100 99 68 90 76 71 88 87
Klebsiella pneumoniae 34 100 R 94 94 94 97 100 100 97 35 94 88 100 100

Outpatient Urine
E. coli 1638 81 60 87 94 94 95 100 100 83 97 82 83 93 93
Klebsiella pneumoniae 262 97 R 98 98 98 98 100 100 95 53 94 89 99 98

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results Susceptibility <50% 50-89% ≥90%
“R” intrinsically resistant or sensitivity <10%
“-“ either not tested or not active
1 for uncomplicated UTI only
 Candida species: % Susceptible (2016-2017)

(dose dependent1)
(standard dose)

Voriconazole
Fluconazole

Fluconazole

Micafungin
# tested
Candida albicans 646 97 3 99 100
C. parapsilosis 126 91 2 98 100
C. glabrata 99 0 93 - 100
C. tropicalis 46 100 9 95 100
C. krusei 34 0 0 100 100
C. unspecified 45 91 0 98 98

Susceptibility <50% 50-89% ≥90%

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results
“-“ no data
* data combined from 2016 and 2017 calendar years (includes both blood stream and non-blood stream isolates)
1 a higher dose of Fluconazole would be indicated

Species in green indicate susceptibility rates from QEII HSC Data due to low number local isolates
 QEII Health Sciences Centre Antibiotic Susceptibility (Oct 2016- Sept 2017)

Inpatients - Gram Negative Isolates: % Susceptible

Piperacillin/Tazobactam
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin

Tetracycline2
Meropenem
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
Ertapenem
# tested**

Ampicillin

SXT/TMP
E. coli 926 80 52 82 93 90 93 99 100 79 97 80 79 97 97
Klebsiella pneumoniae 288 98 R 93 98 96 97 99 100 97 35 90 85 97 97
Klebsiella oxytoca 85 89 R 54 100 94 89 100 100 100 92 100 97 100 100
Citrobacter freundii 37 R R R 62* 62* R 97 97 87 97 89 87 87 89
Enterobacter cloacae 147 R R R 67* 61* R 86 97 97 54 92 89 99 99
Enterobacter
37 R R R 65* 65* R 89 97 95 R 100 92 100 100
aerogenes 4
Serratia marcescens 90 R R R 99 91 - 98 100 90 R 100 21 99 93
Morganella morganii 45 R R R 91 91 98 100 100 89 R 82 24 98 79
Proteus mirabilis 174 99 87 86 99 98 100 99 100 93 R 88 R 94 94
Afermenters
Pseudomonas
319 R R R 88 - 90 R 85 88 - R - 89 95
aeruginosa
Burkholderia cepacia 3 27 R R R 33 15 R R 78 26 - 48 - R R
Stenotrophomonas
36 R R R 39 - - R R 28 - 92 - 19 22
sp.
Acinetobacter
60 R R R 78 18 82 - 100 98 - 98 - 97 100
baumannii complex 3

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results
* may develop resistance on treatment due to inducible AmpC B-lactamase (not Susceptibility <50% 50-89% ≥90%
recommended for treatment for Enterobacter and Citrobacter)
** approximate # tested as not all isolates tested against all antibiotics
“R” intrinsically resistant or sensitivity <10%
“-“ either not tested or not active
1 for uncomplicated UTI only (cephalexin and nitrofurantoin)
2 doxycycline susceptibility can be inferred from tetracycline
3 includes isolates from Oct 2014-Sept 2017 (due to low number of isolates)
4 Enterobacter aerogenes now called Klebsiella aerogenes
 Inpatients - Gram Positive Isolates: % Susceptible (Oct 2016- Sept 2017)

Amoxicillin/Clavulanate

Nitrofurantoin9
Erythromycin

Ciprofloxacin

Levofloxacin

Vancomycin
Clindamycin

doxycycline
Ceftriaxone
Cloxacillin8
# tested**

Ampicillin

SXT/TMP
Penicillin
Staphylococcus aureus 1 538 882 R R 88 - 77 71 83 - 99 98 986 100
MRSA 64 R R R R R 33 16 19 - 100 95 986 98
Coagulase negative
217 372 - - 37 - 58 43 46 - 99 61 926 100
Staphylococcus
Enterococcus faecalis 87 992 99 -7 R R R R 83 - 98 R 28 100
Enterococcus faecium 53 R2 R -7 R R R R R - R R 21 98
Streptococcus pyogenes 4,10
38 1003 1003 1003 1003 1003 84 84 - - - R - 1003
(Group A Streptococcus)
Streptococcus pneumoniae 5,10 64 692 692 69 - 100 - 71 - 98 - - 76 1003

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results
** approximate # tested as not all isolates tested against all antibiotics Susceptibility <50% 50-89% ≥90%
“R” intrinsically resistant or susceptibility < 10%
“-“ either not tested or not active
MRSA = methicillin resistant Staphylococcus aureus
1 includes MRSA (MRSA represents approximately 12% of all S. aureus isolates)
2 inferred susceptibility from other agents
3 predicted susceptibility from literature
4 includes isolates from Oct 2015 to Sept 2017
5 non-CSF isolates (CSF isolates may have different resistance due to lower MIC breakpoints for penicillin and ceftriaxone)
6 Doxycycline susceptibility inferred from tetracycline
7 may be susceptible but not reported (not better than ampicillin)
8 Cefazolin and Cephalexin susceptibilities can be inferred from Cloxacillin
9 for uncomplicated UTI only
10 combined inpatient and outpatient data
 Outpatients - Gram Negative Isolates: % Susceptible (Oct 2016- Sept 2017)

Piperacillin/Tazobactam
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin

Tetracycline2
Meropenem
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
# tested **

Ertapenem
Ampicillin

SXT/TMP
E. coli 7123 87 63 91 97 96 96 100 100 89 97 81 81 94 94
Klebsiella pneumoniae 1057 95 R 94 98 97 95 99 100 96 34 91 85 98 97
Klebsiella oxytoca 159 89 R 55 99 94 94 100 100 99 77 94 95 98 99
Citrobacter freundii 101 R R R 87* 87* 86* 99 99 95 92 87 84 92 93
Enterobacter cloacae 173 R R R 84* 80* 82* 95 97 97 51 88 91 98 95
Enterobacter
79 R R R 90* 87* 87* 98 98 96 14 96 98 100 100
aerogenes 4
Serratia marcescens 111 R R R 100 90 - 96 99 92 R 96 17 99 79
Morganella morganii 59 R R R 85 92 98 98 100 93 R 85 11 85 95
Proteus mirabilis 390 100 88 86 100 100 100 99 100 98 R 88 R 96 97
Afermenters
Pseudomonas
461 R R R 93 - 94 R 87 70 - R - 69 86
aeruginosa
Burkholderia cepacia 33 R R R 30 R R R 61 R - R - R R
Stenotrophomonas
55 R R R 35 R - R R 13 - 91 - 13 R
sp.
Acinetobacter
46 R R R 94 24 90 - 100 98 - 100 - 100 100
baumannii complex 3

All results are rounded to the nearest whole number Susceptibility <50% 50-89% ≥90%
Some isolates may have duplicates included which may alter the results
* may develop resistance on treatment due to inducible AmpC B-lactamase (not recommended for treatment for Enterobacter and Citrobacter)
** approximate # tested as not all isolates tested against all antibiotics
“R” intrinsically resistant or sensitivity <10%
“-“ either not tested or not active
1 for uncomplicated UTI only (cephalexin and nitrofurantoin)
2 doxycycline susceptibility can be inferred from tetracycline
3 includes isolates from Sept 2015 – Oct 2017
4 Enterobacter aerogenes now called Klebsiella aerogenes
 Outpatients - Gram Positive Isolates: % Susceptible (Oct 2016- Sept 2017)

Amoxicillin/Clavulanate

Nitrofurantoin9
Erythromycin

Ciprofloxacin

Levofloxacin
Clindamycin

Vancomycin
doxycycline
Ceftriaxone
Cloxacillin8
# tested**

Ampicillin

SXT/TMP
Penicillin
Staphylococcus aureus 1 949 88 - - 88 - 72 63 84 - 99 97 936 100
MRSA 109 R R R R R 52 27 34 - 99 93 1006 100
Coagulase negative
170 422 - - 42 - 62 49 44 - 99 61 - 98
Staphylococcus
Enterococcus faecalis 240 992 99 -7 R R R R 64 - 98 R 28 100
Enterococcus faecium 63 102 10 -7 R R R R 44 - R R 16 100
Streptococcus pyogenes 4,10
38 1003 1003 1003 1003 1003 84 84 - - - R - 1003
(Group A Streptococcus)
Streptococcus pneumoniae
5,10 64 692 692 69 - 100 - 71 - 98 - - 77 1003

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results Susceptibility <50% 50-89% ≥90%
** approximate # tested as not all isolates tested against all antibiotics
“R” intrinsically resistant or susceptibility < 10%
“-“ either not tested or not active
MRSA = methicillin resistant Staphylococcus aureus
1 includes MRSA (MRSA represents approximately 12% of all S. aureus isolates)
2 inferred susceptibility from other agents
3 predicted susceptibility from literature
4 includes isolates from Oct 2014 to Sept 2016
5 non-CSF isolates (CSF isolates may have higher resistance due to lower MIC breakpoints for penicillin and ceftriaxone)
6 Doxycycline susceptibility inferred from Tetracycline
7 may be susceptible but not reported (not better than ampicillin)
8 Cefazolin and cephalexin susceptibilities can be inferred from Cloxacillin
9 for uncomplicated UTI only
10 combined inpatient and outpatient data
 E. coli and Klebsiella pneumoniae (urinary isolates only): % Susceptible (Oct 2016- Sept 2017)

All results are rounded to the nearest whole number

Piperacillin/Tazobactam
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin

Tetracycline2
Meropenem
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
Ertapenem
# tested**

Ampicillin

SXT/TMP
Inpatient Urine
E. coli 613 80 53 83 93 90 94 100 100 79 97 79 79 90 90
Klebsiella pneumoniae 212 99 R 95 99 97 97 100 100 97 37 92 88 97 98

Outpatient Urine
E. coli 7068 87 63 91 98 96 96 100 100 89 97 81 81 94 94
Klebsiella pneumoniae 1040 95 R 95 98 97 95 99 100 96 34 91 85 98 97
Some isolates may have duplicates included which may alter the results
** approximate # tested as not all isolates tested against all antibiotics
“R” intrinsically resistant or sensitivity <10%
1 for uncomplicated UTI only (cephalexin and nitrofurantoin)
2 Doxycycline susceptibility inferred from Tetracycline

Susceptibility <50% 50-89% ≥90%

 Candida species: % Susceptible (2016-2017)

(dose dependent1)
(standard dose)

Voriconazole
Fluconazole

Fluconazole

Micafungin
# tested
Candida albicans 646 97 3 99 100
C. parapsilosis 126 91 2 98 100
C. glabrata 99 0 93 - 100
C. tropicalis 46 100 9 95 100
C. krusei 34 0 0 100 100
C. unspecified 45 91 0 98 98

Susceptibility <50% 50-89% ≥90%

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results
“-“ no data
* data combined from 2016 and 2017 calendar years (includes both blood stream and non-blood stream isolates)
1 a higher dose of Fluconazole would be indicated
 Colchester East Hants HCC Antibiotic Susceptibility
(January 1, 2017 – December 31, 2017)
Inpatients - Gram Negative Isolates: % Susceptible

Piperacillin/Tazobactam
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin

Tetracycline2
Meropenem
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
# tested **

Ertapenem
Ampicillin

SXT/TMP
E. coli 156 82 63 83 88 88 95 100 100 87 97 83 84 95 97
Klebsiella pneumoniae
35 91 R 91 94 94 88 100 100 94 34 85 88 100 94
ssp pneumoniae
Klebsiella oxytoca 85 89 R 54 100 94 89 100 100 100 92 100 97 100 100
Citrobacter freundii 37 R R R 62* 62* R 97 97 87 97 89 87 87 89
Enterobacter cloacae 147 R R R 67* 61* R 86 97 97 54 92 89 99 99
Enterobacter
37 R R R 65* 65* R 89 97 95 R 100 92 100 100
aerogenes 4
Serratia marcescens 90 R R R 99 91 - 98 100 90 R 100 21 99 93
Morganella morganii 45 R R R 91 91 98 100 100 89 R 82 24 98 79
Proteus mirabilis 34 100 88 74 94 94 100 100 100 97 R 91 R 100 100
Afermenters
Pseudomonas
43 R R R 90 R 83 R 88 86 R R R 90 98
aeruginosa
Burkholderia cepacia 3 27 R R R 33 15 R R 78 26 - 48 - R R
Stenotrophomonas
36 R R R 39 - - R R 28 - 92 - 19 22
sp.
Acinetobacter
60 R R R 78 18 82 - 100 98 - 98 - 97 100
baumannii complex 3

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results Susceptibility <50% 50-89% ≥90%
* may develop resistance on treatment due to inducible AmpC B-lactamase (not
recommended for treatment for Enterobacter and Citrobacter)
** approximate # tested as not all isolates tested against all antibiotics
“R” intrinsically resistant or sensitivity <10%
“-“ either not tested or not active
1 for uncomplicated UTI only (cephalexin and nitrofurantoin)
2 doxycycline susceptibility can be inferred

Species in green indicate susceptibility rates from QEII HSC Data due to low number local isolates
 Inpatients - Gram Positive Isolates: % Susceptible (January 1, 2017 – December 31, 2017)

Amoxicillin/Clavulanate

Nitrofurantoin9
Erythromycin

Ciprofloxacin

Levofloxacin
Clindamycin

Vancomycin
doxycycline
Ceftriaxone
# tested **

Cloxacillin8
Ampicillin

SXT/TMP
Penicillin
Staphylococcus aureus 1 538 882 R R 88 - 77 71 83 - 99 98 986 100
MRSA 64 R R R R R 33 16 19 - 100 95 986 98
Coagulase negative
217 372 - - 37 - 58 43 46 - 99 61 926 100
Staphylococcus
Enterococcus spp 55 942 942 94 - - R R 72 72 93 - 28 100
Enterococcus faecalis 87 992 99 -7 R R R R 83 - 98 R 28 100
Enterococcus faecium 53 R2 R -7 R R R R R - R R 21 98
Streptococcus pyogenes 4,10
38 1003 1003 1003 1003 1003 84 84 - - - R - 1003
(Group A Streptococcus)
Streptococcus pneumoniae
5,10 64 692 692 69 - 100 - 71 - 98 - - 76 1003

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results
** approximate # tested as not all isolates tested against all antibiotics
“R” intrinsically resistant or susceptibility < 10%
“-“ either not tested or not active Susceptibility <50% 50-89% ≥90%
MRSA = methicillin resistant Staphylococcus aureus
1 includes MRSA which represents approximately 12% of all S. aureus isolates
2 inferred susceptibility from other agents.
3 predicted susceptibility from literature
5 non-CSF isolates (CSF isolates may have higher resistance due to lower MIC breakpoints for penicillin and ceftriaxone)
6 doxycycline susceptibility can be inferred
7 may be susceptible but not reported (not better than ampicillin)
8 cefazolin and cephalexin susceptibilities can be inferred from cloxacillin
9 for uncomplicated UTI only
10 primarily urinary isolates (not speciated – see QEII HSC data for specific species)

Species in green indicate susceptibility rates from QEII HSC Data due to low number local isolates
 Outpatients - Gram Negative Isolates: % Susceptible (January 1, 2017 – December 31, 2017)

Piperacillin/Tazobactm
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin

Tetracycline2
Meropenem
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
# tested **

Ertapenem
Ampicillin

SXT/TMP
E. coli 1815 82 59 89 94 94 96 100 100 86 96 79 81 93 93
Klebsiella pneumoniae
284 95 R 97 98 97 98 100 100 99 49 94 91 99 99
ssp pneumonia
Klebsiella oxytoca 60 95 R 57 100 98 97 100 100 100 90 93 100 100 100
Citrobacter freundii 53 R R R 96* 96* 96* 100 100 92 94 68 74 89 89
Enterobacter cloacae
73 R R R 83* 67* 80* 94 100 90 49 85 84 97 97
complex
Serratia marcescens 111 R R R 100 90 - 96 99 92 R 96 17 99 79
Morganella morganii 36 R R R 94 94 100 100 100 89 R 83 14 94 94
Proteus mirabilis 191 98 91 82 99 99 99 100 100 99 R 81 R 95 95
Afermenters
Pseudomonas
150 R R R 95 R 91 R 91 91 R R R 93 100
aeruginosa
Burkholderia cepacia 33 R R R 30 R R R 61 R - R - R R
Stenotrophomonas
55 R R R 35 R - R R 13 - 91 - 13 R
sp.
Acinetobacter
46 R R R 94 24 90 - 100 98 - 100 - 100 100
baumannii complex 3

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results
Includes inpatient and outpatient samples Susceptibility <50% 50-89% ≥90%
* may develop resistance on treatment due to inducible AmpC B-lactamase (not
recommended for treatment for Enterobacter and Citrobacter)
** approximate # tested as not all isolates tested against all antibiotics
“R” intrinsically resistant or sensitivity <10%
“-“ either not tested or not active
1 for uncomplicated UTI only (cephalexin and nitrofurantoin)
2 doxycycline susceptibility can be inferred from tetracycline
3 includes isolates from Sept 2015 – Oct 2017

Species in green indicate susceptibility rates from QEII HSC Data due to low number local isolates
 Outpatients - Gram Positive Isolates: % Susceptible (January 1, 2017 – December 31, 2017)

Amoxicillin/Clavulanate

Nitrofurantoin9
Erythromycin

Ciprofloxacin

Levofloxacin
Clindamycin

Vancomycin
doxycycline
Ceftriaxone
# tested **

Cloxacillin8
Ampicillin

SXT/TMP
Penicillin
Staphylococcus aureus 1 949 88 - R 88 - 72 63 84 - 99 97 936 100
MRSA 109 R R R R R 52 27 34 - 99 93 1006 100
Coagulase negative
217 372 - - 37 - 58 43 46 - 99 61 926 100
Staphylococcus
Enterococcus spp 225 982 98 97 - - R R 68 70 98 - 30 100
Enterococcus faecalis 53 1002 100 100 - - R R 87 87 96 R 38 100
Enterococcus faecium 63 102 10 -7 R R R R 44 - R R 16 100
Streptococcus pyogenes
4,10
38 1003 1003 1003 1003 1003 84 84 - - - R - 1003
(Group A Streptococcus)
Streptococcus
64 692 692 69 - 100 - 71 - 98 - - 77 1003
pneumoniae 5,10

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results Susceptibility <50% 50-89% ≥90%
** approximate # tested as not all isolates tested against all antibiotics
“R” intrinsically resistant or susceptibility < 10%
“-“ either not tested or not active
MRSA = methicillin resistant Staphylococcus aureus
1 includes MRSA which represents approximately 11 % of all S. aureus isolates
2 inferred susceptibility from other agents.
3 predicted susceptibility from literature
5 non-CSF isolates (CSF isolates may have higher resistance due to lower MIC breakpoints for penicillin and ceftriaxone)
6 doxycycline susceptibility can be inferred
7 may be susceptible but not reported (not better than ampicillin)
8 cefazolin and cephalexin susceptibilities can be inferred from cloxacillin
9 for uncomplicated UTI only
10 combined inpatient and outpatient data

Species in green indicate susceptibility rates from QEII HSC Data due to low number local isolates
 E. coli and Klebsiella pneumoniae (urinary isolates only): % Susceptible (January 1, 2017 –
December 31, 2017)

Piperacillin/Tazobactam
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin
Meropenem

Tetracycline
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
Ertapenem
Ampicillin

SXT/TMP
# tested

Inpatient Urine
E. coli 118 83 66 83 87 87 96 100 100 90 97 84 84 98 98
Klebsiella pneumoniae 212 99 R 95 99 97 97 100 100 97 37 92 88 97 98

Outpatient Urine
E. coli 1726 82 59 89 94 94 96 100 100 86 96 79 81 93 93
Klebsiella pneumoniae 266 95 R 97 98 97 98 100 100 98 49 93 91 98 98

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results Susceptibility <50% 50-89% ≥90%
“R” intrinsically resistant or sensitivity <10%
“-“ either not tested or not active
1 for uncomplicated UTI only

Species in green indicate susceptibility rates from QEII HSC Data due to low number local isolates
 Candida species: % Susceptible (2016-2017) - DRAFT

(dose dependent1)
(standard dose)

Voriconazole
Fluconazole

Fluconazole

Micafungin
# tested
Candida albicans 646 97 3 99 100
C. parapsilosis 126 91 2 98 100
C. glabrata 99 0 93 - 100
C. tropicalis 46 100 9 95 100
C. krusei 34 0 0 100 100
C. unspecified 45 91 0 98 98

Susceptibility <50% 50-89% ≥90%

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results
“-“ no data
* data combined from 2016 and 2017 calendar years (includes both blood stream and non-blood stream isolates)
1 a higher dose of Fluconazole would be indicated

Species in green indicate susceptibility rates from QEII HSC Data due to low number local isolates
 Cumberland RHCC Antibiotic Susceptibility (January 1, 2017 to December 31, 2017)

Inpatients - Gram Negative Isolates: % Susceptible

Piperacillin/Tazobactam
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin

Tetracycline2
Meropenem
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
# tested **

Ertapenem
Ampicillin

SXT/TMP
E. coli 101 79 56 86 91 91 97 99 100 71 96 73 80 94 92
Klebsiella pneumoniae
35 77 R 79 82 82 86 94 94 91 40 74 74 100 82
ssp pneumoniae
Klebsiella oxytoca 85 89 R 54 100 94 89 100 100 100 92 100 97 100 100
Citrobacter freundii 37 R R R 62* 62* R 97 97 87 97 89 87 87 89
Enterobacter cloacae 147 R R R 67* 61* R 86 97 97 54 92 89 99 99
Enterobacter
37 R R R 65* 65* R 89 97 95 R 100 92 100 100
aerogenes 4
Serratia marcescens 90 R R R 99 91 - 98 100 90 R 100 21 99 93
Morganella morganii 45 R R R 91 91 98 100 100 89 R 82 24 98 79
Proteus mirabilis 174 99 87 86 99 98 100 99 100 93 R 88 R 94 94
Afermenters
Pseudomonas
39 R R R 97 R 95 R 89 87 R R R 90 100
aeruginosa
Burkholderia cepacia 3 27 R R R 33 15 - R 78 26 - 48 - R R
Stenotrophomonas
36 R R R 39 - - R R 28 - 92 - 19 22
sp.
Acinetobacter
60 R R R 78 18 82 - 100 98 - 98 - 97 100
baumannii complex 3

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results Susceptibility <50% 50-89% ≥90%
* may develop resistance on treatment due to inducible AmpC B-lactamase (not
recommended for treatment for Enterobacter and Citrobacter)
** approximate # tested as not all isolates tested against all antibiotics
“R” intrinsically resistant or sensitivity <10%
“-“ either not tested or not active
1 for uncomplicated UTI only
2 doxycycline susceptibility can be inferred
3 includes isolates from Oct 2014-Sept 2017 (due to low number of isolates)

Species in green indicate susceptibility rates from QEII HSC Data due to low number local isolates
 Inpatients - Gram Positive Isolates: % Susceptible (January 1, 2017 to December 31, 2017)

Amoxicillin/Clavulanate

Nitrofurantoin9
Erythromycin

Ciprofloxacin

Levofloxacin
Clindamycin

Vancomycin
doxycycline
Ceftriaxone
Cloxacillin8
# tested**

Ampicillin

SXT/TMP
Penicillin
Staphylococcus aureus 1 538 882 R R 88 - 77 71 83 - 99 98 986 100
MRSA 64 R R R R R 33 16 19 - 100 95 986 98
Coagulase negative
217 372 - - 37 - 58 43 46 - 99 61 926 100
Staphylococcus
Enterococcus spp 10 44 - 88 88 - - R R 45 - 90 - 41 98
Enterococcus faecalis 87 992 99 -7 R R R R 83 - 98 R 28 100
Enterococcus faecium 53 R2 R -7 R R R R R - R R 21 98
Streptococcus pyogenes 4,10
38 1003 1003 1003 1003 1003 84 84 - - - R - 1003
(Group A Streptococcus)
Streptococcus pneumoniae
5,10 64 692 692 69 - 100 - 71 - 98 - - 76 1003

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results
** approximate # tested as not all isolates tested against all antibiotics
“R” intrinsically resistant or susceptibility < 10%
“-“ either not tested or not active
MRSA = methicillin resistant Staphylococcus aureus
1 includes MRSA which represents approximately 12 % of all S. aureus isolates
2 inferred susceptibility from other agents.
3 predicted susceptibility from literature
5 non-CSF isolates (CSF isolates may have higher resistance due to lower MIC breakpoints for penicillin and ceftriaxone)
6 doxycycline susceptibility can be inferred
7 may be susceptible but not reported (not better than ampicillin)
8 cefazolin and cephalexin susceptibilities can be inferred from cloxacillin
9 for uncomplicated UTI only
10 primarily urinary isolates (not speciated – see QEII HSC data for specific species)

Species in green indicate susceptibility rates from QEII HSC Data due to low number local isolates
Outpatients - Gram Negative Isolates: % Susceptible (January 1, 2017 to December 31, 2017)

Piperacillin/Tazobactam
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin

Tetracycline2
Meropenem
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
# tested **

Ertapenem
Ampicillin

SXT/TMP
E. coli 1223 81 57 91 95 95 97 100 100 81 95 77 81 93 93
Klebsiella pneumoniae
173 91 R 92 94 94 95 99 99 94 39 91 84 96 94
ssp pneumoniae
Klebsiella oxytoca 48 92 R 63 100 94 94 100 100 100 88 100 98 100 100
Citrobacter freundii 101 R R R 87* 87* 86* 99 99 95 92 87 84 92 93
Enterobacter cloacae
30 R R R 80* 77* 80 93 97 93 53 73 83 97 97
complex
Serratia marcescens 111 R R R 100 90 - 96 99 92 R 96 17 99 79
Morganella morganii 59 R R R 85 92 98 98 100 93 R 85 11 85 95
Proteus mirabilis 158 96 64 78 97 97 99 98 99 86 R 63 R 96 96
Afermenters
Pseudomonas
79 R R R 99 R 96 R 92 79 R R R 94 100
aeruginosa
Burkholderia cepacia 33 R R R 30 R R R 61 R - R - R R
Stenotrophomonas
55 R R R 35 R - R R 13 - 91 - 13 R
sp.
Acinetobacter
46 R R R 94 24 90 - 100 98 - 100 - 100 100
baumannii complex 3

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results Susceptibility <50% 50-89% ≥90%
* may develop resistance on treatment due to inducible AmpC B-lactamase (not
recommended for treatment for Enterobacter and Citrobacter)
** approximate # tested as not all isolates tested against all antibiotics
“R” intrinsically resistant or sensitivity <10%
“-“ either not tested or not active
1 for uncomplicated UTI only (cephalexin and nitrofurantoin)
2 doxycycline susceptibility can be inferred
3 includes isolates from Sept 2015 – Oct 2017

Species in green indicate susceptibility rates from QEII HSC Data due to low number local isolates
Outpatients - Gram Positive Isolates: % Susceptible (January 1, 2017 to December 31, 2017)

Amoxicillin/Clavulanate

Nitrofurantoin9
Erythromycin

Ciprofloxacin

Levofloxacin
Clindamycin

Vancomycin
doxycycline
Ceftriaxone
Cloxacillin8
# tested**

Ampicillin

SXT/TMP
Penicillin
Staphylococcus aureus 1 949 88 - - 88 - 72 63 84 - 99 97 936 100
MRSA 109 R R R R R 52 27 34 - 99 93 1006 100
Coagulase negative
79 - - R 59 - 73 41 68 67 99 63 86 100
Staphylococcus
Enterococcus spp 235 - 97 96 - - R R 68 70 94 - 41 100
Enterococcus faecalis 240 992 99 -7 R R R R 64 - 98 R 28 100
Enterococcus faecium 63 102 10 -7 R R R R 44 - R R 16 100
Streptococcus pyogenes 4,10
38 1003 1003 1003 1003 1003 84 84 - - - R - 1003
(Group A Streptococcus)
Streptococcus agalactiae
138 - 100 100 - - 41 38 - 100 99 - R 100
(Group B Streptococcus)
Streptococcus pneumoniae
5,10 64 692 692 69 - 100 - 71 - 98 - - 77 1003

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results Susceptibility <50% 50-89% ≥90%
** approximate # tested as not all isolates tested against all antibiotics
“R” intrinsically resistant or susceptibility < 10%
“-“ either not tested or not active
MRSA = methicillin resistant Staphylococcus aureus
1 includes MRSA which represents approximately 11% of all S. aureus isolates
2 inferred susceptibility from other agents.
3 predicted susceptibility from literature
5 non-CSF isolates (CSF isolates may have higher resistance due to lower MIC breakpoints for penicillin and ceftriaxone)
6 doxycycline susceptibility can be inferred
7 may be susceptible but not reported (not better than ampicillin)
8 cefazolin and cephalexin susceptibilities can be inferred from cloxacillin
9 for uncomplicated UTI only

Species in green indicate susceptibility rates from QEII HSC Data due to low number local isolates
 E. coli and Klebsiella pneumoniae (urinary isolates only): % Susceptible (January 1, 2017 to

Piperacillin/Tazobactam
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin
Meropenem

Tetracycline
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
# tested **

Ertapenem
Ampicillin

SXT/TMP
Inpatient Urine
E. coli 91 80 53 84 90 90 97 99 100 69 95 72 78 93 91
Klebsiella pneumoniae 212 99 R 95 99 97 97 100 100 97 37 92 88 97 98

Outpatient Urine
E. coli 1204 81 57 91 95 95 97 100 100 81 95 77 81 93 93
Klebsiella pneumoniae 167 91 R 92 93 93 95 99 99 95 38 90 84 96 94
December 31, 2017)

All results are rounded to the nearest whole number Susceptibility <50% 50-89% ≥90%
Some isolates may have duplicates included which may alter the results
** approximate # tested as not all isolates tested against all antibiotics
“R” intrinsically resistant or sensitivity <10%
“-“either not tested or not active
1 for uncomplicated UTI only

Species in green indicate susceptibility rates from QEII HSC Data due to low number local isolates
 Candida species: % Susceptible (2016-2017) - DRAFT

(dose dependent1)
(standard dose)

Voriconazole
Fluconazole

Fluconazole

Micafungin
# tested
Candida albicans 646 97 3 99 100
C. parapsilosis 126 91 2 98 100
C. glabrata 99 0 93 - 100
C. tropicalis 46 100 9 95 100
C. krusei 34 0 0 100 100
C. unspecified 45 91 0 98 98

Susceptibility <50% 50-89% ≥90%

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results
“-“ no data
* data combined from 2016 and 2017 calendar years (includes both blood stream and non-blood stream isolates)
1 a higher dose of Fluconazole would be indicated

Species in green indicate susceptibility rates from QEII HSC Data due to low number local isolates
Nova Scotia Health Authority Antibiotic Susceptibility: Eastern Zone January 1, 2017 to December 31, 2017
INPATIENT GRAM NEGATIVE ISOLATES: % SUSCEPTIBLE

Piperacillin/Tazobactam
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin

Tetracycline2

Levofloxacin
Meropenem
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
Ertapenem
# tested **

Ampicillin

SXT/TMP
E. coli 587 100 49 86 100 91 - 100 100 71 95 83 - 90 87 -
Klebsiella pneumoniae 167 - R 90 - 90 100 - 99 88 48 83 - 96 90 -
Klebsiella oxytoca 48 - R 53 - 88 100 - 100 91 85 93 - 100 100 -
Citrobacter freundii 37 R R R 62* 62* R 97 97 87 97 89 87 87 89 -
Enterobacter cloacae 81 R R R - R R - 81 89 55 89 - 100 100 -
Enterobacter -
37 R R R 65* 65* R 89 97 95 R 100 92 100 100
aerogenes5
Serratia marcescens 30 R R R - R - - 100 100 R 100 - 100 83 -
Morganella morganii 45 R R R 91 91 98 100 100 89 R 82 24 98 79 -
Proteus mirabilis 83 - 89 96 - 96 - - 99 95 R 91 - 95 96 -
Afermenters
Pseudomonas -
175 R R R 86 R 81 R 80 74 - R - 90 98
aeruginosa
Burkholderia cepacia3 27 R R R 33 15 R R 78 26 - 48 - R R -
Acinetobacter -
60 R R R 78 18 82 - 100 98 - 98 - 97 100
baumannii complex3
Stenotrophomonas 91
31 R R R 35 R R R R - - 87 - R R
sp.
All results are rounded to the nearest whole number
Some isolates may have duplicates included which may alter the results
* may develop resistance on treatment due to inducible AmpC B-lactamase (not recommended for treatment for
Enterobacter and Citrobacter) <50% 50-89% ≥90%
** approximate # tested as not all isolates tested against all antibiotics Susceptibility
“R” intrinsically resistant or sensitivity <10%
“-“ either not tested or not reported
1 for uncomplicated UTI only (cephalexin and nitrofurantoin)
2 doxycycline susceptibility can be inferred from tetracycline
3 includes isolates from Oct 2014-Sept 2017 (due to low number of isolates)
4 Enterobacter aerogenes now called Klebsiella aerogenes

Species in green indicate susceptibility rates from QEII HSC Data due to low number local isolates
 INPATIENT GRAM POSITIVE ISOLATES: % SUSCEPTIBILE (Jan. to Dec 2017)

Amoxicillin/Clavulanate

Nitrofurantoin8
Erythromycin

Ciprofloxacin

Tetracycline6
Levofloxacin
Clindamycin

Vancomycin
Ceftriaxone
# tested**

Ampicillin

Oxacillin7

SXT/TMP
Penicillin
Staphylococcus
238 982 - - 98 - 80 73 - 100 98 100 98 100
aureus
MRSA 30 R R R R R 50 23 - - 97 100 97 100
Coagulase negative
217 372 - - 37 - 58 43 46 - 99 61 92 100
Staphylococcus
Enterococcus
100 992 99 99 - R R R 64 66 100 R 22 100
faecalis
Enterococcus
51 R R R R R R R R R 31 R 28 98
faecium
MRSA
Streptococcus
pyogenes4,9
38 1003 1003 1003 1003 1003 84 84 - - - R - 1003
(Group A
Streptococcus)
Streptococcus
64 692 692 69 - 100 - 71 - 98 - - 762 1003
pneumoniae 5,9
All results are rounded to the nearest whole number
Some isolates may have duplicates included which may alter the results
** approximate # tested as not all isolates tested against all antibiotics <50% 50-89% ≥90%
“R” intrinsically resistant or susceptibility < 10% Susceptibility
“-“ either not tested or not reported
MRSA = methicillin resistant Staphylococcus aureus
2 inferred susceptibility from other agents.
3 predicted susceptibility from literature
4 includes isolates from Oct 2015 to Sept 2017
5 non-CSF isolates (CSF isolates may have higher resistance due to lower MIC breakpoints for penicillin and ceftriaxone)
6 doxycycline susceptibility can be inferred from tetracycline
7 cefazolin and cephalexin susceptibilities can be inferred from oxacillin
8 for uncomplicated UTI only
9 combined inpatient and outpatient data

Species in green indicate susceptibility rates from QEII HSC Data due to low number local isolates
 OUTPATIENT GRAM NEGATIVE ISOLATES: % SUSCEPTIBLE (Jan. - Dec. 2017)

Piperacillin/Tazobactam
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin

Tetracycline2

Levofloxacin
Meropenem
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
Ertapenem
# tested**

Ampicillin

SXT/TMP
E. coli 3771 - 57 93 100 96 100 - 100 80 95 82 - 93 93 -
Klebsiella pneumoniae 622 - R 98 - 98 - - 100 97 49 95 100 99 98 -
Klebsiella oxytoca 137 - R 68 - 99 - - 100 93 91 96 - 99 96 -
Citrobacter freundii 37 R R R -* -* -* - 97 92 94 92 - 94 94 -
Enterobacter cloacae 199 R R R -* R* -* 100 94 96 53 91 100 99 98 -
Enterobacter -
39 R R R -* R* -* - 100 95 21 97 - 100 100
aerogenes3
Serratia marcescens 66 R R R - R - - 100 97 R 100 - 100 89 -
Morganella morganii 52 - R R - - - - 100 96 R 86 - 100 98 -
Proteus mirabilis 366 - 83 97 - 98 - - 99 90 R 87 - 98 98 -
Afermenters
Pseudomonas -
395 R R R 87 R 89 R 100 81 R R - 94 100
aeruginosa
Burkholderia cepacia 33 R R R 30 R R R 61 R - R - R R -
Stenotrophomonas 80
59 R R R 63 R R R R - - 86 - R R
sp.
Acinetobacter -
41 R R R - 25 85 R 100 98 R 98 - 100 100
baumannii complex

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results
* may develop resistance on treatment due to inducible AmpC B-lactamase (not recommended for treatment for Enterobacter and Citrobacter)
** approximate # tested as not all isolates tested against all antibiotics
“R” intrinsically resistant or sensitivity <10%
“-“ either not tested or not reported Susceptibility <50% 50-89% ≥90%
1 for uncomplicated UTI only (cephalexin and nitrofurantoin)
2 doxycycline susceptibility can be inferred from tetracycline
3 Enterobacter aerogenes now called Klebsiella aerogenes

Species in green indicate susceptibility rates from QEII HSC Data due to low number local isolates
 OUTPATIENT GRAM POSITIVE ISOLATES: % SUSCEPTIBLE (Jan. - Dec. 2017)

Amoxicillin/Clavulanate

Nitrofurantoin9
Erythromycin

Ciprofloxacin

Tetracycline6
Levofloxacin

Vancomycin
Clindamycin
Ceftriaxone
# tested**

Ampicillin

Oxacillin8

SXT/TMP
Penicillin
Staphylococcus aureus 748 992 - - 99 - 80 76 - - 97 99 98 100

MRSA 83 R R R R R 45 12 - - 96 98 89 100

Coagulase negative
170 422 - - 42 - 62 49 44 - 99 61 - 98
Staphylococcus
Enterococcus faecalis 224 992 99 99 - R R 78 80 99 R 22 100
2 7
Enterococcus faecium 63 10 10 - R R R R 44 - R R 16 100
MRSApyogenes
Streptococcus
38 1003 1003 1003 1003 1003 84 84 - - - R - 1003
(Group A Streptococcus) 4,10
Streptococcus pneumoniae
5,10 64 692 692 69 - 100 - 71 - 98 - - 77 1003

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results
** approximate # tested as not all isolates tested against all antibiotics <50% 50-89% ≥90%
“R” intrinsically resistant or susceptibility < 10% Susceptibility
“-“ either not tested or reported
MRSA = methicillin resistant Staphylococcus aureus
2 inferred susceptibility from other agents.
3 predicted susceptibility from literature
4 includes isolates from Oct 2014 to Sept 2016
5 non-CSF isolates (CSF isolates may have higher resistance due to lower MIC breakpoints for penicillin and ceftriaxone)
6 doxycycline susceptibility can be inferred from tetracycline
7 may be susceptible but not reported (not better than ampicillin)
8 cefazolin and cephalexin susceptibilities can be inferred from oxacillin
9 for uncomplicated UTI only
10combined inpatient and outpatient data

Species in green indicate susceptibility rates from QEII HSC Data due to low number local isolates
 E. coli and Klebsiella pneumoniae (urinary isolates only): % Susceptible (Jan. – Dec. 2017)

Piperacillin/Tazobactam
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin

Tetracycline2
Meropenem
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
Ertapenem
Ampicillin

SXT/TMP
# tested

Inpatient Urine
E. coli 385 - 48 86 100 90 - - 100 72 94 82 - 91 88
Klebsiella pneumoniae 91 - R 87 - 87 - - 99 84 51 84 - 94 86

Outpatient Urine
E. coli 3527 - 57 93 - 95 100 - 98 80 95 82 - 93 93
Klebsiella pneumoniae 532 - R 98 - 98 - - 100 99 49 95 100 99 99

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results Susceptibility <50% 50-89% ≥90%
“R” intrinsically resistant or sensitivity <10%
“-“ either not tested or not reported
1
for uncomplicated UTI only (cephalexin and nitrofurantoin)
2
doxycycline susceptibility inferred from tetracycline
 Candida species: % Susceptible (2016-2017)

(dose dependent1)
(standard dose)

Voriconazole
Fluconazole

Fluconazole

Micafungin
# tested
Candida albicans 646 97 3 99 100
C. parapsilosis 126 91 2 98 100
C. glabrata 99 0 93 - 100
C. tropicalis 46 100 9 95 100
C. krusei 34 0 0 100 100
C. unspecified 45 91 0 98 98

Susceptibility <50% 50-89% ≥90%

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results
“-“ no data
* data combined from 2016 and 2017 calendar years (includes both blood stream and non-blood stream isolates)
1 a higher dose of Fluconazole would be indicated

Species in green indicate susceptibility rates from QEII HSC Data due to low number local isolates
 SSRH Antibiotic Susceptibility (Jan 1, 2017 – Dec 31, 2017)

Inpatients - Gram Negative Isolates: % Susceptible

Piperacillin/Tazobactam
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin

Tetracycline2
Meropenem
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
Ertapenem
Ampicillin

SXT/TMP
E. coli # tested
119 81 62 82 88 88 93 100 100 81 93 82 84 95 95
Klebsiella
39 92 R 90 92 92 95 100 97 97 56 95 76 100 97
pneumoniae
Klebsiella oxytoca 85 89 R 54 100 94 89 100 100 100 92 100 97 100 100
Citrobacter freundii 37 R R R 62* 62* R 97 97 87 97 89 87 87 89
Enterobacter cloacae 147 R R R 67* 61* R 86 97 97 54 92 89 99 99
Enterobacter
37 R R R 65* 65* R 89 97 95 R 100 92 100 100
aerogenes
Serratia marcescens 90 R R R 99 91 -3 98 100 90 R 100 21 99 93
Morganella morganii 45 R R R 91 91 98 100 100 89 R 82 24 98 79
Proteus mirabilis 37 100 89 73 92 89 97 100 100 97 R 94 0 92 89
Afermenters
Pseudomonas
319 - - - 88 - 90 R 85 88 - R - 89 95
aeruginosa
Burkholderia cepacia 4 27 - - - 33 15 - - 78 26 - 48 - R R
Stenotrophomonas
36 - - - 39 - - - R 28 - 92 - 19 22
sp.
Acinetobacter
60 - - - 78 18 82 - 100 98 - 98 - 97 100
baumannii complex 4
All results are rounded to the nearest whole number
Some isolates may have duplicates included which may alter the results
** approximate # tested as not all isolates tested against all antibiotics Susceptibility <50% 50-89% ≥90%
* may develop resistance on treatment due to inducible AmpC B-lactamase (not recommended
for treatment for Enterobacter and Citrobacter)
“R” intrinsically resistant or sensitivity <10%
“-“ either not tested or not active
1 Cephalexin should only be used for uncomplicated UTI
2 doxycycline susceptibility can be inferred from tetracycline
3 may be susceptible but not reported
4 includes isolates from Oct 2014-Sept 2017 (due to low number of isolates)
5 Enterobacter aerogenes now called Klebsiella aerogenes

Species in green indicate susceptibility rates from Capital Health Data due to low local isolates
 Inpatients - Gram Positive Isolates: % Susceptible

Amoxicillin/Clavulanate

Nitrofurantoin9
Erythromycin

Ciprofloxacin

Levofloxacin
Clindamycin

Vancomycin
doxycycline
Ceftriaxone
Cloxacillin8
# tested**

Ampicillin

SXT/TMP
Penicillin
Staphylococcus aureus 1 538 882 R R 88 - 77 71 83 - 99 98 986 100
MRSA 64 R R R R R 33 16 19 - 100 95 986 98
Coagulase negative
217 372 - - 37 - 58 43 46 - 99 61 926 100
Staphylococcus
Enterococcus faecalis 87 992 99 -7 R R R R 83 - 98 R 28 100
Enterococcus faecium 53 R2 R -7 R R R R R - R R 21 98
MRSApyogenes
Streptococcus 144 IR IR IR 64 19 35 99 98 95 99
4,10
38 1002 1002 1003 1002 1002 84 84 - - - R - 1003
(Group A Streptococcus)
Streptococcus
64 692 692 69 - 100 - 71 - 98 - - 76 1003
pneumoniae 5,10
All results are rounded to the nearest whole number
Some isolates may have duplicates included which may alter the results
** approximate # tested as not all isolates tested against all antibiotics Susceptibility <50% 50-89% ≥90%
“R” intrinsically resistant or susceptibility < 10%
“-“ either not tested or not active
MRSA = methicillin resistant Staphylococcus aureus
1 includes MSSA and MRSA
2 inferred susceptibility from other agents (may be more active than penicillin but not tested)
3 predicted susceptibility from literature
4 includes isolates from Oct 2015 to Sept 2017
5 non-CSF isolates (CSF isolates may have different resistance due to lower MIC breakpoints for penicillin and ceftriaxone)
6 doxycycline susceptibility inferred from tetracycline
7 may be susceptible but not reported (not better than ampicillin)
8 cefazolin and cephalexin susceptibilities can be inferred from cloxacillin
9 for uncomplicated UTI only
10 combined inpatient and outpatient data

Species in green indicate susceptibility rates from Capital Health Data due to low local isolates
 Outpatients - Gram Negative Isolates: % Susceptible

Piperacillin/Tazobactam
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin

Tetracycline2
Meropenem
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
Ertapenem
Ampicillin

SXT/TMP
# tested
E. coli 1298 88 65 89 94 94 96 100 100 86 96 81 81 94 95
Klebsiella
165 93 R 93 96 96 95 100 100 93 33 93 81 97 93
pneumoniae
Klebsiella oxytoca 159 89 R 55 99 94 94 100 100 99 77 94 95 98 99
Citrobacter freundii 101 R R R 87* 87* 86* 99 99 95 92 87 84 92 93
Enterobacter cloacae 35 R R R 89* 80* 89* 100 97 97 51 91 97 100 100
Enterobacter
79 R R R 90* 87* 87* 98 98 96 14 96 98 100 100
aerogenes 5
Serratia marcescens 111 R R R 100 90 -3 96 99 92 R 96 17 99 79
Morganella morganii 59 R R R 85 92 98 98 100 93 R 85 11 85 95
Proteus mirabilis 101 100 90 79 99 99 100 100 100 91 R 85 R 97 96
Afermenters
Pseudomonas
50 - - - 96 - 92 - 100 88 - R - 100 100
aeruginosa
Burkholderia cepacia 33 - - - 30 - - - 61 R - R - R R
Stenotrophomonas
55 - - - 35 R - - R 13 - 91 - 13 R
sp.
Acinetobacter
46 - - - 94 24 - - - 98 - 100 - 100 100
baumannii complex 4
All results are rounded to the nearest whole number
Some isolates may have duplicates included which may alter the results Susceptibility <50% 50-89% ≥90%
Includes inpatient and outpatient samples
* may develop resistance on treatment due to inducible AmpC B-lactamase (not recommended for treatment for Enterobacter and Citrobacter)
“R” intrinsically resistant or sensitivity <10%
“-“ either not tested or not active
1 Cephalexin should only be used for uncomplicated UTI
2 doxycycline susceptibility can be inferred from tetracycline
3 may be susceptible but not reported
4 includes isolates from Sept 2015 – Oct 2017
5 Enterobacter aerogenes now called Klebsiella aerogenes

Species in green indicate susceptibility rates from Capital Health Data due to low local isolates
 Outpatients - Gram Positive Isolates: % Susceptible

Amoxicillin/Clavulanate

Nitrofurantoin9
Erythromycin

Ciprofloxacin

Levofloxacin
Clindamycin

Vancomycin
doxycycline
Ceftriaxone
Cloxacillin8
# tested**

Ampicillin

SXT/TMP
Penicillin
Staphylococcus aureus 1 103 - - R 90 - 83 72 91 88 100 100 97 100
MRSA 109 R R R R R 52 27 34 - 99 93 1006 100
Coagulase negative
170 427 - - 42 - 62 49 44 - 99 61 - 98
Staphylococcus
Enterococcus faecalis 66 - 98 98 - - R R 76 76 100 - 39 100
Enterococcus faecium 63 102 10 -7 R R R R 44 - R R 16 100
MRSA
Streptococcus pyogenes10
38 1002 1002 100 1002 1002 84 84 - - - R - 1003
(Group A Streptococcus)
Streptococcus
64 692 692 69 - 100 - 71 - 98 - - 77 1003
pneumoniae 5,10

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results Susceptibility <50% 50-89% ≥90%
Includes inpatient and outpatient samples
** approximate # tested as not all isolates tested against all antibiotics
“R” intrinsically resistant or susceptibility < 10%
“-“ either not tested or not active
MRSA = methicillin resistant Staphylococcus aureus
1 includes MRSA
2 inferred susceptibility from other agents.
3 predicted susceptibility from literature
4 includes isolates from Oct 2014 to Sept 2016
5 non-CSF isolates (CSF isolates may have higher resistance due to lower MIC breakpoints for penicillin and ceftriaxone)
6 doxycycline susceptibility inferred from tetracycline
7 may be susceptible but not reported (not better than ampicillin)
8 cefazolin and cephalexin susceptibilities can be inferred from cloxacillin
9 for uncomplicated UTI only
10 combined inpatient and outpatient data

Species in green indicate susceptibility rates from Capital Health Data due to low local isolates
 E. coli and Klebsiella pneumoniae (urinary isolates only): % Susceptible

Piperacillin/Tazobactam
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin
Meropenem

Tetracycline
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
Ertapenem
Ampicillin

SXT/TMP
# tested

Inpatient Urine
E. coli 114 82 62 83 88 88 93 100 100 81 94 81 85 94 94
Klebsiella pneumoniae 34 91 R 88 91 91 94 100 100 97 62 94 73 100 97

Outpatient Urine
E. coli 1229 88 65 89 94 94 96 100 100 87 97 81 81 95 95
Klebsiella pneumoniae 156 94 R 93 96 96 95 100 100 94 33 92 82 97 94

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results
“R” intrinsically resistant or sensitivity <10%
“-“ either not tested or not active
1 for uncomplicated UTI only
 Candida species: % Susceptible (2016-2017)*

(dose dependent1)

Voriconazole
Fluconazole

Fluconazole

Micafungin
# tested
Candida albicans 646 97 3 99 100
C. parapsilosis 126 91 2 98 100
C. glabrata 99 0 93 - 100
C. tropicalis 46 100 9 95 100
C. krusei 34 0 0 100 100
C. unspecified 45 91 0 98 98

Susceptibility <50% 50-89% ≥90%

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results
“-“ no data
* data combined from 2016 and 2017 calendar years (includes both blood stream and non-blood stream isolates)
1 a higher dose of fluconazole would be indicated

Species in green indicate susceptibility rates from Capital Health Data due to low local isolates
 YRH Antibiotic Susceptibility (Jan 1, 2017- Dec 31, 2017)

Inpatients - Gram Negative Isolates: % Susceptible

Piperacillin/Tazobactam
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin

Tetracycline2
Meropenem
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
Ertapenem
Ampicillin

SXT/TMP
# tested
E. coli 107 84 58 87 91 91 93 100 100 76 97 77 70 91 91
Klebsiella
288 98 R 93 98 96 97 99 100 97 35 90 85 97 97
pneumoniae
Klebsiella oxytoca 85 89 R 54 100 94 89 100 100 100 92 100 97 100 100
Citrobacter freundii 37 R R R 62* 62* R 97 97 87 97 89 87 87 89
Enterobacter cloacae 147 R R R 67* 61* R 86 97 97 54 92 89 99 99
Enterobacter
37 R R R 65* 65* R 89 97 95 R 100 92 100 100
aerogenes
Serratia marcescens 90 R R R 99 91 -3 98 100 90 R 100 21 99 93
Morganella morganii 45 R R R 91 91 98 100 100 89 R 82 24 98 79
Proteus mirabilis 38 100 95 100 100 100 100 100 100 86 R 78 R 97 100
Afermenters
Pseudomonas
30 - - - 93 - 85 - 96 90 - R - 100 100
aeruginosa
Burkholderia cepacia 27 - - - 33 15 - - 78 26 - 48 - R R
Stenotrophomonas
36 - - - 39 - - - R 28 - 92 - 19 22
sp.
Acinetobacter
60 - - - 78 18 82 - 100 98 - 98 - 97 100
baumannii complex
All results are rounded to the nearest whole number
Some isolates may have duplicates included which may alter the results
** approximate # tested as not all isolates tested against all antibiotics Susceptibility <50% 50-89% ≥90%
* may develop resistance on treatment due to inducible AmpC B-lactamase (not recommended
for treatment for Enterobacter and Citrobacter)
“R” intrinsically resistant or sensitivity <10%
“-“ either not tested or not active
1 Cephalexin should only be used for uncomplicated UTI
2 doxycycline susceptibility can be inferred from tetracycline
3 may be susceptible but not reported
4 includes isolates from Oct 2014-Sept 2017 (due to low number of isolates)
5 Enterobacter aerogenes now called Klebsiella aerogenes

Species in green indicate susceptibility rates from Capital Health Data due to low local isolates
 Inpatients - Gram Positive Isolates: % Susceptible

Amoxicillin/Clavulanate

Nitrofurantoin9
Erythromycin

Ciprofloxacin

Levofloxacin
Clindamycin

Vancomycin
doxycycline
Ceftriaxone
Cloxacillin8
# tested**

Ampicillin

SXT/TMP
Penicillin
Staphylococcus aureus 1 538 882 R R 88 - 77 71 83 - 99 98 986 100
MRSA 64 R R R R R 33 16 19 - 100 95 986 98
Coagulase negative
217 372 - - 37 - 58 43 46 - 99 61 926 100
Staphylococcus
Enterococcus faecalis 87 992 99 -7 R R R R 83 - 98 R 28 100
Enterococcus faecium 53 R2 R -7 R R R R R - R R 21 98
MRSApyogenes4
Streptococcus 144 IR IR 2 IR 2 64 19 35 99 98 95 99
38 1002 100 1003 100 1002 84 84 - - - R - 1003
(Group A Streptococcus)
Streptococcus
64 692 692 69 - 100 - 71 - 98 - - 76 1003
pneumoniae 5,10
All results are rounded to the nearest whole number
Some isolates may have duplicates included which may alter the results
Susceptibility <50% 50-89% ≥90%
** approximate # tested as not all isolates tested against all antibiotics
“R” intrinsically resistant or susceptibility < 10%
“-“ either not tested or not active
MRSA = methicillin resistant Staphylococcus aureus
1 includes MSSA and MRSA
2 inferred susceptibility from other agents (may be more active than penicillin but not tested)
3 predicted susceptibility from literature
4 includes isolates from Oct 2015 to Sept 2017
5 non-CSF isolates (CSF isolates may have different resistance due to lower MIC breakpoints for penicillin and ceftriaxone)
6 doxycycline susceptibility inferred from tetracycline
7 may be susceptible but not reported (not better than ampicillin)
8 cefazolin and cephalexin susceptibilities can be inferred from cloxacillin
9 for uncomplicated UTI only
10 combined inpatient and outpatient data

Species in green indicate susceptibility rates from Capital Health Data due to low local isolates
 Outpatients - Gram Negative Isolates: % Susceptible

Piperacillin/Tazobactam
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin

Tetracycline2
Meropenem
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
Ertapenem
Ampicillin

SXT/TMP
# tested
E. coli 1210 87 65 94 97 97 97 100 100 89 98 84 80 93 94
Klebsiella
170 93 R 96 96 96 95 100 100 92 45 89 85 100 96
pneumoniae
Klebsiella oxytoca 49 98 R 69 100 98 98 100 98 100 96 100 94 100 100
Citrobacter freundii 101 R R R 87* 87* 86* 99 99 95 92 87 84 92 93
Enterobacter cloacae 42 R R R 88* 76* 71* 100 98 100 64 88 95 100 100
Enterobacter
79 R R R 90* 87* 87* 98 98 96 14 96 98 100 100
aerogenes
Serratia marcescens 111 R R R 100 90 -3 96 99 92 R 96 17 99 79
Morganella morganii 59 R R R 85 92 98 98 100 93 R 85 11 85 95
Proteus mirabilis 101 100 92 87 98 98 100 100 99 94 R 94 R 95 95
Afermenters
Pseudomonas
80 - - - 91 - 89 - 95 79 - R - 93 100
aeruginosa
Burkholderia cepacia 33 - - - 30 - - - 61 R - R - R R
Stenotrophomonas
55 - - - 35 R - - R 13 - 91 - 13 R
sp.
Acinetobacter
46 - - - 94 24 - - - 98 - 100 - 100 100
baumannii complex
All results are rounded to the nearest whole number
Some isolates may have duplicates included which may alter the results
Includes inpatient and outpatient samples Susceptibility <50% 50-89% ≥90%
* may develop resistance on treatment due to inducible AmpC B-lactamase (not
recommended for treatment for Enterobacter and Citrobacter)
“R” intrinsically resistant or sensitivity <10%
“-“ either not tested or not active
1 Cephalexin should only be used for uncomplicated UTI
2 doxycycline susceptibility can be inferred from tetracycline
3 may be susceptible but not reported
4 includes isolates from Sept 2015 – Oct 2017
5 Enterobacter aerogenes now called Klebsiella aerogenes

Species in green indicate susceptibility rates from Capital Health Data due to low local isolates
 Outpatients - Gram Positive Isolates: % Susceptible

Amoxicillin/Clavulanate

Nitrofurantoin9
Erythromycin

Ciprofloxacin

Levofloxacin
Clindamycin

Vancomycin
doxycycline
Ceftriaxone
Cloxacillin8
# tested**

Ampicillin

SXT/TMP
Penicillin
Staphylococcus aureus 1 140 - - R 87 - 80 75 81 84 99 100 98 100
MRSA 109 R R R R R 52 27 34 - 99 93 1006 100
Coagulase negative
170 427 - - 42 - 62 49 44 - 99 61 - 98
Staphylococcus
Enterococcus faecalis 240 992 99 -7 R R R R 64 - 98 R 28 100
Enterococcus faecium 63 102 10 -7 R R R R 44 - R R 16 100
MRSApyogenes
Streptococcus
38 1002 1002 100 1002 1002 84 84 - - - R - 1003
(Group A Streptococcus)
Streptococcus
64 692 692 69 - 100 - 71 - 98 - - 77 1003
pneumoniae 5,10
All results are rounded to the nearest whole number
Some isolates may have duplicates included which may alter the results
Includes inpatient and outpatient samples Susceptibility <50% 50-89% ≥90%
** approximate # tested as not all isolates tested against all antibiotics
“R” intrinsically resistant or susceptibility < 10%
“-“ either not tested or not active
MRSA = methicillin resistant Staphylococcus aureus
1 includes MRSA
2 inferred susceptibility from other agents.
3 predicted susceptibility from literature
4 includes isolates from Oct 2014 to Sept 2016
5 non-CSF isolates (CSF isolates may have higher resistance due to lower MIC breakpoints for penicillin and ceftriaxone)
6 doxycycline susceptibility inferred from tetracycline
7 may be susceptible but not reported (not better than ampicillin)
8 cefazolin and cephalexin susceptibilities can be inferred from cloxacillin
9 for uncomplicated UTI only
10 combined inpatient and outpatient data

Species in green indicate susceptibility rates from Capital Health Data due to low local isolates
 E. coli and Klebsiella pneumoniae (urinary isolates only): % Susceptible

Piperacillin/Tazobactam
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin
Meropenem

Tetracycline
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
Ertapenem
Ampicillin

SXT/TMP
# tested

Inpatient Urine
E. coli 97 84 59 87 91 91 92 100 100 77 99 77 71 91 90
Klebsiella pneumoniae 212 99 R 95 99 97 97 100 100 97 37 92 88 97 98

Outpatient Urine
E. coli 1097 87 66 95 97 97 95 100 97 88 95 84 80 94 99
Klebsiella pneumoniae 159 93% R 96 96 96 94 100 100 91 44 88 84 100 96

All results are rounded to the nearest whole number

Susceptibility <50% 50-89% ≥90%
Some isolates may have duplicates included which may alter the results
“R” intrinsically resistant or sensitivity <10%
“-“ either not tested or not active
1 for uncomplicated UTI only
Species in green indicate susceptibility rates from Capital Health Data due to low local isolates
 Candida species: % Susceptible (2016-2017)*

(dose dependent1)

Voriconazole
Fluconazole

Fluconazole

Micafungin
# tested
Candida albicans 646 97 3 99 100
C. parapsilosis 126 91 2 98 100
C. glabrata 99 0 93 - 100
C. tropicalis 46 100 9 95 100
C. krusei 34 0 0 100 100
C. unspecified 45 91 0 98 98

Susceptibility <50% 50-89% ≥90%

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results
“-“ no data
* data combined from 2016 and 2017 calendar years (includes both blood stream and non-blood stream isolates)
1 a higher dose of fluconazole would be indicated

Species in green indicate susceptibility rates from Capital Health Data due to low local isolates
 VRH Antibiotic Susceptibility (Jan 1, 2017 – Dec 31, 2017)

Inpatients - Gram Negative Isolates: % Susceptible

Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Piperacillin/Tazobacta

Nitrofurantoin 1
Ciprofloxacin

Tetracycline2
Meropenem
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
Ertapenem
Ampicillin

SXT/TMP
# tested

m
E. coli 173 84 64 86 92 92 95 100 100 88 98 85 79 96 96
Klebsiella
54 96 R 91 94 92 96 100 100 96 31 92 86 98 98
pneumoniae
Klebsiella oxytoca 85 89 R 54 100 94 89 100 100 100 92 100 97 100 100
Citrobacter freundii 37 R R R 62* 62* R 97 97 87 97 89 87 87 89
Enterobacter cloacae 147 R R R 67* 61* R 86 97 97 54 92 89 99 99
Enterobacter
37 R R R 65* 65* R 89 97 95 R 100 92 100 100
aerogenes
Serratia marcescens 90 R R R 99 91 -3 98 100 90 R 100 21 99 93
Morganella morganii 45 R R R 91 91 98 100 100 89 R 82 24 98 79
Proteus mirabilis 69 100 73 68 82 85 97 100 98 79 R 85 R 91 91
Afermenters
Pseudomonas
35 - - - 89 - 97 - 100 94 - R - 91 100
aeruginosa
Burkholderia cepacia4 27 - - - 33 15 - - 78 26 - 48 - R R
Stenotrophomonas
36 - - - 39 - - - R 28 - 92 - 19 22
sp.
Acinetobacter
60 - - - 78 18 82 - 100 98 - 98 - 97 100
baumannii complex4
All results are rounded to the nearest whole number
Some isolates may have duplicates included which may alter the results
** approximate # tested as not all isolates tested against all antibiotics Susceptibility <50% 50-89% ≥90%
* may develop resistance on treatment due to inducible AmpC B-lactamase (not recommended
for treatment for Enterobacter and Citrobacter)
“R” intrinsically resistant or sensitivity <10%
“-“ either not tested or not active
1 Cephalexin should only be used for uncomplicated UTI
2 doxycycline susceptibility can be inferred from tetracycline
3 may be susceptible but not reported
4 includes isolates from Oct 2014-Sept 2017 (due to low number of isolates)
5 Enterobacter aerogenes now called Klebsiella aerogenes

Species in green indicate susceptibility rates from Capital Health Data due to low local isolates
 Inpatients - Gram Positive Isolates: % Susceptible
All results are rounded to the nearest whole number

Amoxicillin/Clavulanate

Nitrofurantoin9
Erythromycin

Ciprofloxacin

Levofloxacin
Clindamycin

Vancomycin
doxycycline
Ceftriaxone
Cloxacillin8
# tested**

Ampicillin

SXT/TMP
Penicillin
Staphylococcus aureus 1 60 - - - 90 - 85 73 88 88 100 100 99 100
MRSA 64 R R R R R 33 16 19 - 100 95 986 98
Coagulase negative
217 372 - - 37 - 58 43 46 - 99 61 926 100
Staphylococcus
Enterococcus faecalis 87 992 99 -7 R R R R 83 - 98 R 28 100
Enterococcus faecium 53 R2 R -7 R R R R R - R R 21 98
MRSA
Streptococcus 144 IR IR IR 64 19 35 99 98 95 99
pyogenes4,10 38 1002 1002 1003 1002 1002 84 84 - - - R - 1003
(Group A Streptococcus)
Streptococcus
64 692 692 69 - 100 - 71 - 98 - - 76 1003
pneumoniae 5,10
All results are rounded to the nearest whole number
Some isolates may have duplicates included which may alter the results
** approximate # tested as not all isolates tested against all antibiotics Susceptibility <50% 50-89% ≥90%
“R” intrinsically resistant or susceptibility < 10%
“-“ either not tested or not active
MRSA = methicillin resistant Staphylococcus aureus
1 includes MSSA and MRSA
2 inferred susceptibility from other agents (may be more active than penicillin but not tested)
3 predicted susceptibility from literature
4 includes isolates from Oct 2015 to Sept 2017
5 non-CSF isolates (CSF isolates may have different resistance due to lower MIC breakpoints for penicillin and ceftriaxone)
6 doxycycline susceptibility inferred from tetracycline
7 may be susceptible but not reported (not better than ampicillin)
8 cefazolin and cephalexin susceptibilities can be inferred from cloxacillin
9 for uncomplicated UTI only
10 combined inpatient and outpatient data

Species in green indicate susceptibility rates from Capital Health Data due to low local isolates
 Outpatients - Gram Negative Isolates: % Susceptible

Piperacillin/Tazobactam
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin

Tetracycline2
Meropenem
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
Ertapenem
Ampicillin

SXT/TMP
# tested
E. coli 2825 89 66 91 94 94 97 100 100 87 98 84 81 96 96
Klebsiella
383 96 R 95 96 96 95 100 99 96 38 90 91 99 98
pneumoniae
Klebsiella oxytoca 44 95 R 45 100 95 93 100 100 98 93 98 93 100 100
Citrobacter freundii 101 R R R 87* 87* 86* 99 99 95 92 87 84 92 93
Enterobacter cloacae 44 R R R 86* 81* 86* 100 95 100 59 93 95 98 98
Enterobacter
79 R R R 90* 87* 87* 98 98 96 14 96 98 100 100
aerogenes5
Serratia marcescens 39 R R R 100 79 - 100 100 95 R 100 31 100 92
Morganella morganii 59 R R R 85 92 98 98 100 93 R 85 11 85 95
Proteus mirabilis 197 100 80 72 93 93 100 100 100 93 R 93 R 95 96
Afermenters
Pseudomonas
128 - - - 99 - 98 - 98 94 - 2 - 97 100
aeruginosa
Burkholderia cepacia 33 - - - 30 - - - 61 R - R - R R
Stenotrophomonas
55 - - - 35 R - - R 13 - 91 - 13 R
sp.
Acinetobacter
46 - - - 94 24 - - - 98 - 100 - 100 100
baumannii complex4

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results Susceptibility <50% 50-89% ≥90%
Includes inpatient and outpatient samples
* may develop resistance on treatment due to inducible AmpC B-lactamase (not recommended for treatment for Enterobacter and Citrobacter)
“R” intrinsically resistant or sensitivity <10%
“-“ either not tested or not active
1 Cephalexin should only be used for uncomplicated UTI
2 doxycycline susceptibility can be inferred from tetracycline
3 may be susceptible but not reported
4 includes isolates from Sept 2015 – Oct 2017
5 Enterobacter aerogenes now called Klebsiella aerogenes

Species in green indicate susceptibility rates from Capital Health Data due to low local isolates
 Outpatients - Gram Positive Isolates: % Susceptible

Amoxicillin/Clavulanate

Nitrofurantoin9
Erythromycin

Ciprofloxacin

Levofloxacin
Clindamycin

Vancomycin
doxycycline
Ceftriaxone
Cloxacillin8
# tested**

Ampicillin

SXT/TMP
Penicillin
Staphylococcus aureus 1 199 - - - 87 - 80 73 88 88 99 98 98 99
MRSA 109 R R R R R 52 27 34 - 99 93 1006 100
Coagulase negative 88
33 - - - 60 - 67 39 76 76 100 - 100
Staphylococcus
Enterococcus faecalis 240 992 99 -7 R R R R 64 - 98 R 28 100
Enterococcus faecium 63 102 10 -7 R R R R 44 - R R 16 100
MRSA
Streptococcus pyogenes10
38 1002 1002 100 1002 1002 84 84 - - - R - 1003
(Group A Streptococcus)
Streptococcus
64 692 692 69 - 100 - 71 - 98 - - 77 1003
pneumoniae 5, 10

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results Susceptibility <50% 50-89% ≥90%
Includes inpatient and outpatient samples
** approximate # tested as not all isolates tested against all antibiotics
“R” intrinsically resistant or susceptibility < 10%
“-“ either not tested or not active
MRSA = methicillin resistant Staphylococcus aureus
1 includes MRSA
2 inferred susceptibility from other agents.
3 predicted susceptibility from literature
4 includes isolates from Oct 2014 to Sept 2016
5 non-CSF isolates (CSF isolates may have higher resistance due to lower MIC breakpoints for penicillin and ceftriaxone)
6 doxycycline susceptibility inferred from tetracycline
7 may be susceptible but not reported (not better than ampicillin)
8 cefazolin and cephalexin susceptibilities can be inferred from cloxacillin
9 for uncomplicated UTI only
10 combined inpatient and outpatient data

Species in green indicate susceptibility rates from Capital Health Data due to low local isolates
 E. coli and Klebsiella pneumoniae (urinary isolates only): % Susceptible

Piperacillin/Tazobactam
Amoxicillin/Clavulanate

Cefazolin (Cephalexin 1)

Nitrofurantoin 1
Ciprofloxacin
Meropenem

Tetracycline
Ceftazidime

Tobramycin
Ceftriaxone

Gentamicin
Ertapenem
Ampicillin

SXT/TMP
# tested

Inpatient Urine
E. coli 158 84 62 86 92 92 95 100 100 88 97 83 78 95 96
Klebsiella pneumoniae 46 95 R 91 93 93 95 100 100 95 30 90 88 98 98

Outpatient Urine
E. coli 2723 89 66 90 94 94 97 100 100 87 97 84 81 96 96
Klebsiella pneumoniae 360 98 R 94 95 95 95 100 99 96 37 90 90 99 98

All results are rounded to the nearest whole number

Susceptibility <50% 50-89% ≥90%
Some isolates may have duplicates included which may alter the results
“R” intrinsically resistant or sensitivity <10%
“-“ either not tested or not active
1 for uncomplicated UTI only
 Candida species: % Susceptible (2016-2017)*

(dose dependent1)

Voriconazole
Fluconazole

Fluconazole

Micafungin
# tested
Candida albicans 646 97 3 99 100
C. parapsilosis 126 91 2 98 100
C. glabrata 99 0 93 - 100
C. tropicalis 46 100 9 95 100
C. krusei 34 0 0 100 100
C. unspecified 45 91 0 98 98

Susceptibility <50% 50-89% ≥90%

All results are rounded to the nearest whole number

Some isolates may have duplicates included which may alter the results
“-“ no data
* data combined from 2016 and 2017 calendar years (includes both blood stream and non-blood stream isolates)
1 a higher dose of fluconazole would be indicated

Species in green indicate susceptibility rates from Capital Health Data due to low local isolates